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In psychiatry, the selection of antipsychotics and antidepressants is generally led by
a trial-and-error approach. The prescribing of these medications is complicated by
sub-optimal efficacy and high rates of adverse drug reactions (ADRs). These both
contribute to poor levels of adherence. Pharmacogenetics (PGx) considers how genetic
variation can influence an individual’s response to a drug. Pharmacogenetic testing
is a tool that could aid clinicians when selecting psychotropic medications, as part
of a more personalized approach to prescribing. This may improve the use of and
adherence to these medications. Yet to date, the implementation of PGx in mental
health environments in the United Kingdom has been slow. This review aims to identify
the current barriers and enablers to the implementation of PGx in psychiatry and
determine how this can be applied to the uptake of PGx by NHS mental health providers.
A systematic searching strategy was developed, and searches were carried out on the
PsychInfo, EmBase, and PubMed databases, yielding 11 appropriate papers. Common
barriers to the implementation of PGx included cost, concerns over incorporation into
current workflow and a lack of knowledge about PGx; whilst frequent enablers included
optimism that PGx could lead to precision medicine, reduce ADRs and become a more
routine part of psychiatric clinical care. The uptake of PGx in psychiatric care settings
in the NHS should consider and overcome these barriers, while looking to capitalize on
the enablers identified in this review.
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INTRODUCTION
Prior to the COVID-19 pandemic the estimated social and
economic cost of mental health illness in England was £119
billion a year (O’Shea and Bell, 2020). Mental Health (MH)
illnesses are a leading cause of health burden worldwide (Vos
et al., 2015). Medication can treat those with mental illnesses;
antidepressants and antipsychotics are commonly prescribed.
However, in some patients the benefit of such pharmacological
interventions is hindered by a lack of therapeutic response and
significant adverse drug reactions (ADRs) (Sinyor et al., 2010;
Huhn et al., 2019). Approximately 30% of people diagnosed with
schizophrenia are treatment resistant and similarly up to 50%
of people prescribed an antidepressant do not respond initially
(Meltzer, 1997; Fava, 2003; Lally et al., 2016). An estimated 40%
of people taking antidepressants will experience ADRs (Bull et al.,
2002). Antipsychotics can cause a variety of adverse effects (Huhn
et al., 2019). Limited efficacy and ADRs, combined with the
relapsing-remitting nature of many mental illnesses, contributes
to poor adherence to these drug classes (Semahegn et al.,
2020). Furthermore, non-adherence to medication is a predictor
of poorer health outcomes in MH patient populations, with
increased risk of relapse (Leucht et al., 2012; Kato et al., 2021).
Pharmacogenomics is the study of how genetic variation can
influence response to medication (Roden, 2006). These variations
are often single nucleotide polymorphisms (SNPs), where a
substitution occurs at a single base in the genome resulting in a
different genetic sequence (Butler, 2012). Previous studies suggest
that over 90% of the population carry at least one change that may
alter drug response (Van Driest et al., 2014; Bush et al., 2016; Ji
et al., 2016; Mostafa et al., 2019). PGx has the potential to make
a significant impact in the field of psychiatry. The NHS has seen
prescribing of psychotropic medication increase in recent years
(Wilson, 2020). Approximately 10% of the United Kingdom adult
population are prescribed an antidepressant (Taylor et al., 2019).
During the COVID-19 pandemic, antidepressant prescribing in
the NHS increased by four million items, leading to a £140
million increase in spending compared with the previous year
(Rabeea et al., 2021). Antipsychotics are a mainstay of treatment
in schizophrenia. The selection of these medications is largely
driven by a trial-and-error approach. The implementation of PGx
in the field of psychiatry has the potential to improve this, by
moving current practice toward a more personalized approach
of prescribing, considering patient genetic profiles. There is
hope that this could increase the efficacy and reduce adverse
drug reactions (ADRs) associated with psychotropic medications
(Manchia et al., 2020).
Pharmacogenetics can influence drug response in two ways,
either by altering the pharmacokinetics or pharmacodynamics of
a drug (Roden, 2006). Focus so far in psychiatric PGx has been
on pharmacokinetics. The cytochrome P450 family has been well
studied (Bousman et al., 2021) and are an important group of
metabolic enzymes, with humans possessing over 30 isoenzymes,
of which six are responsible for metabolizing over 90% of drugs
(Stavropoulou et al., 2018). In psychiatric PGx, the genes coding
for the CYP2D6 and CYP2C19 isoenzymes have been studied
most extensively (van Westrhenen et al., 2020). An estimated 36%
and 62% of people worldwide have enzyme variants that affect
the function of these two enzymes, respectively (Koopmans et al.,
2021). Most psychotropics are metabolized by these enzymes; as
such genetic variations of these enzymes can impact upon the
pharmacokinetics of psychotropic medications (Hiemke et al.,
2018). This can result in poor therapeutic response if the active
compound is cleared too quickly, or an increased risk of ADRs
if there is a reduced capacity to clear the drug from the plasma
(Fleeman et al., 2011). So far, the evidence base for actionability,
based on pharmacodynamic pharmacogenes is limited. Common
psychotropic drug-gene interactions can be seen in Figure 1.
Knowledge of which drugs are implicated by drug-
gene interactions (DGIs), caused by genetic variations in
pharmacogenes is increasing (Peters et al., 2014; England, 2016;
Maggo et al., 2019; Pratt et al., 2019, 2021). PharmGKB1 and
CPIC2 databases provide information on DGIs, such as the
evidence base supporting DGIs and suggested actions where
applicable. The recommendations are graded by strength of
evidence. Several pharmacogenetic tests are now available,
however only a limited number of tests are relevant to psychiatry.
Bousman C. et al. (2019) suggested a minimum genetic testing
panel for use in psychiatry should include 16 allelic variants
across five genes (CYP2D6, CYP2C9, CYP2C19, HLA-A, and
HLA-B) (Bousman C. et al., 2019). Recommendations for
CYP2C19, CYP2C9, and CYP2D6 genotyping have also been put
forward (Pratt et al., 2018, 2019, 2021).
Despite examples of localized PGx use in MH clinical practice
in some countries, to our knowledge the uptake of PGx in MH
settings in the United Kingdom has been limited to date (Maggo
et al., 2019). In the United Kingdom, the NHS now has a strategy
to implement personalized medicine as part of a wider policy
effort to increase the uptake of genomic medicine. The NHS
genomic medicine service has been set up to help deliver this and
aims for PGx to be a routine part of NHS care by 2025 (England,
2016). Before this can happen, the way in which PGx is integrated
into the NHS and its position in clinical care pathways needs to
be investigated. Implementation science can play a key role in
ensuring that the uptake of PGx has a positive impact on clinical
practice (Peters et al., 2014).
This mini review, therefore, aims to look at how PGx can
potentially be implemented in psychiatry, by identifying enablers
that help facilitate the uptake of PGx in mental health and
determine factors acting as barriers to the integration of PGx in
mental health care settings.
METHODS
This mini review used a systematic search strategy to
identify suitable studies for inclusion. It adhered to the
Preferred Reporting Items for Systematic Review (PRISMA)
principles (Page et al., 2021) (see Supplementary Appendix
1). A Population, Intervention, Comparator, Outcome,
Settings (PICOS) tool was used to identify the relevant
1https://www.pharmgkb.org/
2https://cpicpgx.org/
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FIGURE 1 | Adapted from Bousman C. et al. (2019) and information presented on https://www.pharmgkb.org/- a network analysis detailing common psychotropic
drugs with their associated pharmacogenes. CYP2D6 and CYP2C19 are common metabolic pathways for a range of antidepressants and antipsychotics. Also
noted is the drug-gene interaction between HLA-B and Phenytoin/Carbamazepine, a well-documented pharmacogenetic interaction.
keywords and Medical Subject Headings (MeSH) words
(Miller and Forrest, 2001).
Inclusion criteria were developed prior to undertaking the
searches, to select the most appropriate studies for the review.
Both qualitative and quantitative studies collecting primary data
from healthcare professionals and patients exploring viewpoints
and perspectives on implementing PGx in psychiatry were
included. Conference abstracts, expert opinion, anecdotal pieces,
and articles not written in English were excluded, as were
controlled trials and cohort studies, as the purpose of the
review was not to evaluate the clinical utility of using PGx in
psychiatry, but rather to identify potential enablers and barriers
to its implementation.
Between April 14th and July 7th 2021, PubMed, EmBase, and
PsychInfo databases were searched. The following terms were
used in the searches: “pharmacogenomics,” “pharmacogenetics,”
“pharmacogenetic testing,” “psychiatry,” “mental health,” and
“mental illness.” One researcher (AJ) screened the titles and
abstracts of the search results. Following this, the methods of
included studies were evaluated to determine the type of data
collected. Once appropriate papers were identified, full texts
were screened and included papers were critically appraised. In
total 11 papers were identified as appropriate to be included
(see Supplementary Appendix 2).
A Microsoft Office Excel spreadsheet, adapted from the
Critical Appraisal Skills Programme (CASP) checklist for
qualitative studies checklist was developed to facilitate data
extraction and critical appraisal (Long et al., 2020) by one
researcher (AJ). For each of the included studies, the following
data was extracted and stored in the spreadsheet: title,
author, publication year, aims, sample size and characteristics,
data collection method, data analysis method, study findings,
strengths, limitations, barriers, and enablers.
Barriers and enablers identified from both qualitative and
quantitative primary data, were synthesized into key themes
and sub-themes using thematic analysis, by one researcher (AJ)
following discussions between AJ, BF, and SM. These themes
are presented as sub-headings in the Section “Results.” Key
themes are presented as individual sub-headings, while sub-
themes that emerged from a limited number of included studies
or that did not link to a key theme, were grouped together
in a miscellaneous group presented in Sections “Miscellaneous:
Trust, Discrimination and Replacing Clinical Judgment” for
barriers and “Miscellaneous: Improving Patient Experience
With Medications” for enablers. This review summarizes these
findings and, in the discussion, offers suggestions about how
these identified barriers and enablers can be considered in the
NHS as PGx is integrated into psychiatric clinical care in the
United Kingdom in the future.
RESULTS
By evaluating the papers included in this review, a range of
barriers and enablers to implementing PGx in psychiatry were
identified. These were categorized into four main barrier themes
and four main enabler themes, listed in order of how strongly
these themes emerged from the studies. Sub-themes were also
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identified, that although relevant, emerged less commonly from
the studies selected. There was a total of three sub-themes
identified as barriers and two sub-themes identified as enablers.
A summary of the barriers and enablers extracted from the
included studies can be found in Table 1.
Of the included studies, seven were conducted in the
United States (Shishko et al., 2015; Thompson et al., 2015;
Goodspeed et al., 2019; Liko et al., 2020; McCarthy et al., 2020;
Vest et al., 2020; Kastrinos et al., 2021), with the remaining studies
being conducted in Canada (Walden et al., 2015), France (Laplace
et al., 2021), Singapore (Chan et al., 2017), and New Zealand
(Dunbar et al., 2012). Three of the studies gathered patient
perspectives about PGx (Liko et al., 2020; McCarthy et al., 2020;
Kastrinos et al., 2021), while the remaining studies gathered
HCPs viewpoints on PGx (Dunbar et al., 2012; Shishko et al.,
2015; Thompson et al., 2015; Walden et al., 2015; Chan et al.,
2017; Goodspeed et al., 2019; McCarthy et al., 2020; Vest et al.,
2020; Laplace et al., 2021). Data collection methods varied
with some studies opting for focus groups (Goodspeed et al.,
2019; Vest et al., 2020), while one conducted semi-structured
interviews (Liko et al., 2020) and other studies collected data
using a survey (Shishko et al., 2015; Thompson et al., 2015;
Walden et al., 2015; Kastrinos et al., 2021) or questionnaire
(Dunbar et al., 2012; Chan et al., 2017; McCarthy et al., 2020;
Laplace et al., 2021). The study setting varied also, with the
majority of studies being conducted in secondary care settings
(Dunbar et al., 2012; Shishko et al., 2015; Thompson et al., 2015;
Walden et al., 2015; Chan et al., 2017; Goodspeed et al., 2019;
Liko et al., 2020; McCarthy et al., 2020), while one was carried
out in both primary and secondary care settings (Vest et al.,
2020), and two studies were unspecified (Kastrinos et al., 2021;
Laplace et al., 2021). A summary of the sample, data collection
methods, barriers and enablers for each study can be found in
Supplementary Appendix 2.
Barriers
Cost and Funding of Pharmacogenetics
Several studies found that both patients and healthcare
professionals (HCPs) had concerns over the cost of PGx. In a
United States study by Liko et al. (2020), cost influenced patients’
decision-making: one cited that if the costs were lower or covered
by insurance, they would be more inclined to have the test done.
It was also highlighted that paying for the test may be perceived
as more beneficial if the patient has tried and failed several
pharmacotherapies. Likewise, clinicians in Singapore surveyed
by Chan et al. (2017) discovered over 94% of respondents were
concerned about cost, making it the biggest perceived risk of PGx
testing within the survey. A similar survey among United States
psychiatric pharmacists by Shishko et al. (2015), showed a lack
of funding or expense to be the main reason for not offering
PGx testing, with only a third of respondents agreeing that
benefits outweigh the costs from a clinical perspective. Cost was
also raised as an issue by clinicians who were interviewed after
ordering a PGx test for use in a United States psychiatric clinic in
TABLE 1 | Summary of barriers and enablers extracted from each study.
Barriers:
Cost or funding Dunbar et al. (2012), Shishko et al. (2015), Chan et al. (2017), Liko et al.
(2020), Laplace et al. (2021)
Lack of knowledge and current evidence base about PGx Shishko et al. (2015), Chan et al. (2017), Vest et al. (2020), Laplace
et al. (2021)
Incorporation into current workflow Dunbar et al. (2012), Shishko et al. (2015), Goodspeed et al. (2019),
Vest et al. (2020)
Misinterpretation of results Liko et al. (2020), Vest et al. (2020)
Fear of discrimination based on PGx results McCarthy et al. (2020), Laplace et al. (2021)
Concerns PGx could replace clinical judgment Dunbar et al. (2012), Laplace et al. (2021)
Trust in PGx results vendor Goodspeed et al. (2019)
Lack of clear guidelines about PGx in psychiatry Chan et al. (2017)
Risk of psychological distress for patients Laplace et al. (2021)
Enablers:
Perception PGx will lead to precision prescribing Dunbar et al. (2012), Thompson et al. (2015), Shishko et al. (2015),
Chan et al. (2017), Liko et al. (2020), Vest et al. (2020)
Interest in the use of PGx Shishko et al. (2015), Chan et al. (2017), Liko et al. (2020), McCarthy
et al. (2020), Vest et al. (2020), Kastrinos et al. (2021)
Aid clinician-patient relationship Goodspeed et al. (2019), Vest et al. (2020), Dunbar et al. (2012)
Belief PGx will become a routine part of practice Shishko et al. (2015), Thompson et al. (2015), Walden et al. (2015),
Laplace et al. (2021)
Belief PGx can help reduce ADRs Dunbar et al. (2012), Shishko et al. (2015), Laplace et al. (2021)
Low risk of psychological distress by receiving PGx results McCarthy et al. (2020), Kastrinos et al. (2021)
Hope that PGx can guide prescribing decisions McCarthy et al. (2020)
Belief that PGx could be useful for those with previously
unsuccessful treatment
Laplace et al. (2021)
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a study by Dunbar et al. (2012). Likewise, in the study of French
psychiatrists by Laplace et al. (2021), 86% of respondents raised
cost as a barrier. In Dunbar et al. (2012); Chan et al. (2017),
Laplace et al. (2021), the context of which cost was perceived as a
barrier was not explored.
Lack of Knowledge, Evidence Base, and Clinical
Guidelines About Pharmacogenetics
Concerns were raised by mental health (MH) providers regarding
clinicians’ lacking the knowledge about PGx required to
implement PGx into their practice. Vest et al. (2020) conducted
focus groups with MH prescribers, both psychiatrists and family
doctors in the United States. They cited a lack of knowledge about
the evidence supporting PGx use in psychiatry and a limited
current evidence base. United States psychiatric pharmacists
surveyed by Shishko et al. (2015) mirrored these points, with
nearly half of respondents perceiving themselves as completely
or somewhat unaware about PGx. In the same way, psychiatrists
and psychiatric pharmacists surveyed by Chan et al. (2017)
expressed how they lack knowledge about PGx in psychiatry,
beyond the role of HLA testing in Carbamazepine prescribing.
A lack of clear guidelines was also identified as a barrier to clinical
implementation. Laplace et al. (2021) echoed these findings, with
61% of respondents claiming they lacked sufficient training and
knowledge about PGx, and 94% agreeing professional guidelines
about PGx use in psychiatry were “unclear or not clear at all.”
Incorporation of Pharmacogenetics Into Current
Workflow
An issue raised in five of the studies (Dunbar et al., 2012; Shishko
et al., 2015; Goodspeed et al., 2019; Vest et al., 2020; Laplace
et al., 2021) was uncertainty about how to incorporate PGx into
current workflow processes. Vest et al. (2020) found participants
felt PGx would be difficult to adopt into current practice, with
concerns over finding the time to educate patients about PGx
during a consultation. Delaying prescribing, by 3 days in this
study, while waiting for PGx results was also expressed as a
concern when compared to standard current practice. Moreover,
Dunbar et al. (2012) found the average wait for results was
8 days and the upper limit was 42 days. Goodspeed et al. (2019)
conducted a focus group with MH clinicians following use of
a prototype system reporting PGx data and found users were
concerned over how to include PGx reports into current clinical
workflow and increased consultation time. How to connect PGx
reports to patient medical records was also raised as a point
of contention. Similar issues were also raised by clinicians after
ordering a PGx test in Dunbar et al. (2012). They also described
the delay in receiving the results as being a reason for not using
PGx data. Likewise, a small number of psychiatric pharmacists in
Shishko et al. (2015) indicated that PGx was too time consuming.
Furthermore, 64% of participants in Laplace et al. (2021) were
concerned about the delay in prescribing that testing may cause.
Misinterpreting Pharmacogenetics Data
Another barrier was the potential for misinterpretation of PGx
information. Vest et al. (2020) reported mental health and
primary care providers being given PGx results in a traffic-light
style report. However, they showed unease over the potential for
misinterpretation of this system, especially by patients. Likewise,
patients in Liko et al. (2020) demonstrated misinterpretation
of PGx reports, the color-coded traffic light system misleading
patients that “green bin” medications are drugs that should work
and “red bin” to be medications that would not work. Rather
these color-coded systems are a guide to the severity of drug-
gene interaction.
Miscellaneous: Trust, Discrimination and Replacing
Clinical Judgment
Subsidiary themes raised less often included concern PGx could
replace clinician experience and clinical judgment. Clinicians
questioned by Dunbar et al. (2012) expressed reluctance over
the idea that PGx test results could take over selection of
treatment rather than treating the clinical presentation of a
patient. Similarly, a minority of respondents in Laplace et al.
(2021) were anxious that PGx could lead to “loss of clinic.”
Clinicians using a prototype clinical decision support tool that
incorporated PGx data in Goodspeed et al. (2019), described
a lack of trust in the data displayed, stemming from previous
experiences using clinical support tools.
There were concerns over the use of PGx data being used
to discriminate against patients. Patients surveyed in McCarthy
et al. (2020) study of attitudes toward PGx in patients with
treatment resistant depression, overall rejected the notion of
fearing discrimination based on results. But there were significant
differences in race, with non-white groups having overall greater
concern about discrimination.
Enablers
Perceived Value of Pharmacogenetics
Most studies found that both HCPs and patients are hopeful
that PGx information can improve the precision of prescribing
and help guide medication selection. Vest et al. (2020) found
primary care and MH providers were hopeful PGx data would
help them identify more effective treatments and avoid some
of the current trial and error process. Similarly, Chan et al.
(2017) found the majority of clinicians surveyed perceived PGx
as being useful for identifying suitable medications for treatment.
Shishko et al. (2015) found that psychiatric pharmacists believed
PGx could be useful in guiding the medication selection and
that PGx would become a standard part of clinical practice.
Thompson et al. (2015) surveyed psychiatrists and obtained
similar findings. Liko et al. (2020) found that prior to testing,
the majority of patients were hopeful PGx would help identify
the right medication for them. One participant, although
skeptical, went on to explain they would expect higher or
lower dosage following the use of a psychiatric PGx test.
Following the test, some patients perceived it as valuable and
another tool to help clinicians choose medication. Likewise,
McCarthy et al. (2020) found patients were largely favorable
toward PGx testing and strongly endorsed statements about
PGx predicting medicines that may be poorly tolerated or less
efficacious. Respondents in Laplace et al. (2021) overwhelmingly
felt PGx could improve response to treatment with over 98%
agreeing on this.
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Patient Interest in Pharmacogenetics
Patients surveyed in two studies by McCarthy et al. (2020);
Kastrinos et al. (2021) had positive outlooks overall on the
use of PGx in psychiatry. Kastrinos et al. (2021) demonstrated
a high level of interest among patients and positive attitudes
toward the use of PGx, while McCarthy et al. (2020) found
patients strongly agreed with PGx testing, if it can help them find
appropriate treatment and allow patients to plan for the future
more effectively.
Improving Patient Engagement
Clinicians reported that the use of PGx data can aid the
relationship with the patient and make them more open to
the use of medication by alleviating concerns relating to the
use of medicines. Dunbar et al. (2012) reported that the use
of PGx report in consultations helped build trust and rapport
between the clinician and patient, acting as a tool for engagement.
Similarly, Goodspeed et al. (2019) found PGx reports helped
ease patient concerns around starting medication and improved
communication of the results. Likewise, Vest et al. (2020)
described how clinicians reported PGx testing can increase
patient inclination to use medication and overcome resistance
relating to medications and side effects.
Belief Pharmacogenetics Will Become a Routine Part
of Practice
Several of the included studies assessed participants’ beliefs
about the future of PGx in psychiatry. Shishko et al. (2015)
found only 17% disagreed that PGx would be actively used in
clinics/hospitals in 10 years. In Walden et al. (2015), following
the use of a PGx test, 80% of practitioners agreed PGx will become
standard practice when prescribing psychiatric medications. This
is echoed by psychiatrists in Thompson et al. (2015), where 85%
believed PGx would become standard treatment. In the same
way 70% of participants in Laplace et al. (2021), believed PGx
would become routine clinical practice. Some studies go further
and attempt to determine what position PGx would have within
psychiatric clinical practice. Chan et al. (2017); Goodspeed et al.
(2019) found participants would be more likely to use PGx in
patients with previous poor tolerability or lack of response in
treatment resistant illness. Laplace et al. (2021) echoed this with
66% of participants expressing they would not necessarily use
PGx in all depression cases, but 85% would do so in treatment
resistant cases.
Miscellaneous: Improving Patient Experience With
Medications
With respect to the psychological impact of PGx results on
patients, two studies found a low risk for negative consequences
when receiving the results (McCarthy et al., 2020; Kastrinos et al.,
2021). Kastrinos et al. (2021) evaluated psychiatric patient views
on PGx, in the context of uncertainty management theory, found
patients scored highly for wanting to reduce uncertainty (by
receiving results) and low for wanting to escalate uncertainty.
While McCarthy et al. (2020) showed patients assessed showed
low levels of concern about coping with PGx results, with only 3%
endorsing an inability to emotionally cope with the result. This
study also showed there was no apparent relationship between
severity of depression and ability to cope with PGx results.
Doctors surveyed by Laplace et al. (2021) agreed, with fewer
than 25% believing there was a risk of psychological distress for
patients following PGx testing.
Clinicians were also found to believe use of PGx could
help reduce the likelihood of ADRs occurring. Shishko et al.
(2015) found over two-thirds of psychiatric pharmacists agreed
PGx could reduce the likelihood of adverse events happening.
Similarly, clinicians in Dunbar et al. (2012) were found to predict
fewer adverse events to be experienced by patients when PGx had
informed drug and dose selection. Further comments were made
explaining that because of this the therapeutic relationship could
improve and adherence would increase.
DISCUSSION
This review has highlighted a range of barriers and enablers to
the uptake of PGx in mental health care settings. Some of these
factors are driven by patient beliefs, while others are primarily
from a healthcare professionals (HCPs) perspective and some
factors are shared by both patients and HCPs.
In line with previous research, cost and funding was identified
as a barrier to implementation (McKinnon et al., 2007; Klein
et al., 2017). Although this was identified as a barrier, it would
be reasonable to expect the cost of pharmacogenetic testing to
continue to decrease, making this less of an obstacle in the
future. One could also argue cost is a perceived barrier to
implementation. A limitation to many of the studies that found
cost as a perceived barrier, was that they did not explore cost in
depth, such as in the context of cost-effectiveness or cost-benefit.
Rather they explored cost in general terms. Cost-effectiveness of
psychiatric PGx was beyond the scope of this review, therefore
for further information we would refer the reader to a recent
systematic review; an economic evaluation on psychiatric PGx
(Karamperis et al., 2021). This shows early studies assessing cost-
effectiveness are promising but are limited by small sample sizes
and high heterogeneity, and as such more research is needed.
Therefore, although cost is currently perceived as a barrier to the
uptake of PGx in psychiatry, evidence may accumulate in the
longer-term supporting the cost-effective use of PGx-informed
prescribing, by finding a more appropriate treatment quicker and
avoiding the currently deployed trial-and-error approach.
Studies assessing cost savings and cost-effectiveness (Hicks
et al., 2015, 2017; Dan Wellings, 2020; Tsermpini et al., 2020;
Programme, 2021; van Westrhenen et al., 2021) have been carried
out, however are from countries without a publicly funded health
service, such as the United States. The implementation of PGx
in mental health settings in the United Kingdom would likely
be NHS-funded, through existing commissioning pathways. As
such, patient perspectives on the cost of using PGx may differ
and they may be less concerned about the cost of testing, and
potentially concentrate more on whether it is a clinically effective
intervention. A 2019 study found 80% of respondents felt the
NHS is facing a major or severe funding crisis (Dan Wellings,
2020) and it is possible that the public would support ways to
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improve efficiency of NHS spending, potentially via improving
prescribing in mental health through the cost-effective use of
PGx. Whereas in non-taxpayer funded healthcare systems, the
patient may be expected to pay for pharmacogenetic testing.
Therefore, the debate around the cost of PGx differs slightly in
context, dependent on how healthcare is funded in each country.
A lack of knowledge about PGx, particularly in relation to
psychiatry, amongst HCPs was identified as another barrier.
Opportunities to educate HCPs should be sought, such as
the Masters in Genomic Medicine currently funded by the
NHS Genomics Education Programme (2021). This will help
bridge the gap in knowledge about PGx and help ensure that
professionals in the NHS are equipped with the skills to use PGx
in practice. Undergraduate courses for HCPs should also look to
integrate PGx training. A lack of guidance on the use of PGx was
also found. Therefore, guidelines recently published by the Dutch
Clinical Psychiatric Association will be a useful starting point for
mental HCPs, in addition to those already created by CPIC (Hicks
et al., 2015, 2017; van Westrhenen et al., 2021). As more evidence
emerges these guidelines should be updated. Studies evaluating
the clinical utility of PGx are ongoing, which will add to the
evidence-base we currently have on PGx (Tsermpini et al., 2020).
Incorporation of PGx into current practice was also
highlighted as a key barrier. HCPs were found to be concerned
about how they would find the time to discuss PGx with
their patients and the delay in prescribing while they wait for
PGx results prior to prescribing medication. A way to facilitate
consultations about PGx with patients, would be the development
of resources for patients to look at and read. Furthermore,
a multi-disciplinary approach, to ensure it is not the sole
responsibility of the prescribing clinician to inform the patient
about PGx and its associated pros and cons, would help balance
the increased workload from PGx across the multidisciplinary
team. It is also a possibility that prescribing workload would
decrease in the long-term, if PGx can improve the precision and
accuracy of prescribing. With the correct training, pharmacists
would be well situated to offer patients counseling about PGx
and assist prescribers in making PGx-informed prescribing
decisions. Future research should aim to evaluate the outcomes
of pharmacist led PGx services. Moreover, the model in which
the NHS wishes to adopt when implementing PGx in mental
health should be explored. Many companies offering PGx testing,
also offer clinical decision support (CDS) as part of their service.
CDS could overcome the issue of PGx being time consuming
for clinicians, by outsourcing the workload. A drawback of
this would of course be cost and potential underutilization of
clinicians with relevant skills working for the NHS already,
such as pharmacists who would be well placed to support
prescribers with PGx.
The delay in prescribing differed among the studies
undertaking PGx testing. This is possibly due to slower
technology being used in older studies, as in the study by Dunbar
et al. (2012). But clearly, delaying prescribing while waiting
for PGx test results is an issue. If patients are acutely unwell,
delaying prescribing may cause more harm than good, if they
require prompt treatment. However, an initial slight delay in
prescribing, to find the most appropriate medication, could
be offset in the long run by reducing the time to therapeutic
response by reducing the trial-and-error approach routinely
adopted in current practice. Furthermore, the delay in receiving
PGx results would likely be overcome following implementation
of robust pathways for PGx referrals and large-scale rollout
and commissioning of facilities to perform PGx testing for
the NHS. Additionally, a medicine could be prescribed with
a follow-up consultation planned, to adjust the dose or drug
selection based on PGx results once obtained. Pre-emptive
testing (van der Wouden et al., 2019) is another model that could
be adopted, which would remove delay in prescribing as a barrier
to PGx implementation.
Linked to educating patients about PGx, is the potential risk of
misinterpreting PGx data which was also identified as a barrier.
Again, development of psychiatry specific PGx resources for
patients could act as an aid when consulting patients about PGx.
Clear explanation of the meaning of PGx reports will be key
to overcoming the risk of misinterpretation by patients. Again,
pharmacists are well placed to offer this counseling to patients.
A further potential barrier raised by both HCPs and patients
was the fear of PGx being used in discriminatory ways. This is
a valid concern and future research should ensure that study
participants are recruited from more diverse backgrounds, to
ensure results of such studies reflect as much as possible the
whole population. A limitation to many of the patient studies in
this review was that often patients were white and middle-aged
(Liko et al., 2020; McCarthy et al., 2020; Kastrinos et al., 2021).
Furthermore, a possibility in the future is that new treatments are
reserved for those with a particular genotype, in which a drug
demonstrates better effectiveness. Exploration of the impact this
may have, and patient education will be key to avoid service users
feeling discriminated against.
This review found that belief about PGx improving the
precision of prescribing resonated amongst patients and HCPs.
Current data from trials investigating psychiatry PGx, comparing
treatment as usual (TAU) vs PGx-informed prescribing decisions
demonstrate improved symptom scores and tolerability (Hall-
Flavin et al., 2012, 2013; Winner et al., 2013; Singh, 2015; Pérez
et al., 2017; Bradley et al., 2018; Greden et al., 2019). With regards
to efficacy, two meta-analyses found PGx-informed treatment
for major depressive disorder leads to improved response rate
(Rosenblat et al., 2018; Bousman C. A. et al., 2019). However,
these meta-analyses were limited by high heterogeneity and risk
of bias in the included studies. Therefore, although early studies
are promising, data from larger scale studies examining a wider
range of MH conditions, using a variety of drug classes and
more diverse patient populations are needed to corroborate these
early findings. Large scale multi-center trials are ongoing; the
hope is that they will provide further insight into the value of
PGx in managing MH problems in psychiatry and primary care.
More focus on antipsychotics is also required, with current work
mainly focusing on assessing the utility of PGx in antidepressant
prescribing (Herbert et al., 2018; Tsermpini et al., 2020).
Linked to the finding that clinicians believe PGx can improve
the precision of prescribing, is the notion that PGx will become
a more routine part of practice. However, a possible limitation to
the studies included is the lack of exploration about where PGx
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may fit into existing care pathways. Although some of the studies
made attempts to determine where clinicians see PGx fitting into
existing care pathways, an overall perspective was not established.
Limited examples from the studies indicate clinicians would be
inclined to use PGx in patients with previous poor tolerability
or lack of response to medications. Future research should aim
to determine practitioner perspectives on this, to help inform
implementation of PGx into existing care pathways.
Related to this, is the belief among clinicians that PGx-
informed prescribing would lead to fewer ADRs. ADRs
contribute 6.5% of hospital admissions in the United Kingdom
and ADRs are a leading cause for discontinuing psychotropic
medication (Pirmohamed et al., 2004; Velligan et al., 2017).
If patients are taking medications that are better matched to
their genetic profile, they may experience fewer side effects.
A study demonstrated better antidepressant tolerability following
PGx-informed treatment selection (Pérez et al., 2017). This
study shows that evidence is slowly accumulating regarding
PGx improving medication tolerability, which should alleviate
concerns relating to a lack of evidence base being a barrier to
PGx implementation. Further studies are warranted to investigate
if PGx-informed treatment selection improves tolerability
of antipsychotics.
Patients were found to have a keen interest in PGx. A key to
the successful uptake of PGx in psychiatry in the NHS will be
acceptability for patients. The process should include involving
patients and the public early on in decisions regarding the
implementation of PGx services in the NHS. Further studies
should seek to confirm these patient perspectives in users of NHS
mental health services.
Regarding the importance of patients being active participants
in treatment decisions wherever possible, this review found HCPs
believe that PGx could improve engagement and discussions with
patients around the topic of medication. Often in psychiatry,
patients can be unwilling to take medication, a systematic review
found average rate of non-adherence with antipsychotics to be
approximately 40% (Lacro et al., 2002). Similar non-adherence
rates were found for other psychotropic drug classes (Semahegn
et al., 2020). Guiding treatment based on an individual’s genetic
profile, could prove invaluable in reaching out to patients
hesitant about medication. A study demonstrated that adherence
in psychiatric patients improved following a PGx-informed
intervention (Fagerness et al., 2014). Further studies should
seek to assess the psychological impact on the patient following
PGx-informed treatment in the context of their views about
medication and their relationship with clinicians.
This review found there was low potential for a negative
psychological impact on the patient from having a PGx test. This
is plausible, since discovering an individual’s PGx profile predicts
only the response to a medication, not a prediction of disease
state. Therefore, unlike the potential negative psychological
impact of having a genetic test, we would not anticipate such
consequences following a PGx test (Oliveri et al., 2018). Patients
may be less apprehensive about learning the findings from a PGx
test compared with a prognostic genetic test. This is supported
by the findings in this review, that patients are generally open to
having a PGx test done, more research is needed to validate this.
There are some limitations to the studies evaluated in
this review. Firstly, most of the studies in the review were
conducted in the United States, which does not have a publicly
funded healthcare system. Therefore, the transferability of
the findings from these studies needs to be confirmed by
conducting studies with HCPs and patients in countries that
have publicly funded healthcare systems, such as the NHS in the
United Kingdom. Many studies only took on board viewpoints
from a limited number of HCPs, such as general practitioners
(GPs), psychiatrists, and psychiatric pharmacists. We know
that the mental health multidisciplinary team is much larger
than these professionals, therefore future research could aim
to evaluate the viewpoints of other professions, namely nurses,
occupational therapists, social workers, and carers who all play a
big role in patient care.
Thus far much of the PGx in psychiatry research has focused
on the use of PGx in depression and related to prescribing
antidepressants. Further studies should look to broaden the scope
of research into PGx in psychiatry, with focus on other drug
classes such as antipsychotics and mood stabilizers, in different
MH conditions such as schizophrenia and bipolar disorder.
Further exploration of antidepressant use in anxiety disorders
is also warranted. Investigation of the role of PGx in managing
psychiatric conditions in those with physical health conditions
and polypharmacy should also be prioritized. Further studies
should also focus on evaluating the clinical outcomes of patients
who received PGx-informed psychiatric prescribing, for example
length of stay in hospital and time spent in illness remission.
Future research should also aim to assess the position of PGx
in clinical pathways by exploring which patients would benefit
the most from the use of PGx and where in care pathways it is
best deployed. It is likely that any uptake of PGx in NHS mental
health services will be driven by cost-effectiveness, therefore
health economics research will be important in determining the
next steps for PGx in psychiatry in the United Kingdom.
Due to this field being specialized, a limitation of the review
is that there is only a small number of papers available looking
at PGx implementation in psychiatry. Because of this, the study
population, country, and clinical setting studied within the
included papers are highly heterogenous. As such generalizations
made about barriers and enablers identified in this review are
limited in nature, due to the similarity in methodologies adopted
amongst the included studies. Another limitation is that the
review did not compare barriers and enablers in psychiatry
to other clinical specialties, this would have been beyond the
scope of this review.
CONCLUSION
In conclusion, this review provides a detailed analysis of
several barriers and enablers to implementing PGx in clinical
mental health practice. As the NHS continues to build on the
foundation it has laid for the uptake of genomic medicine,
services can consider these barriers and enablers when designing
care pathways that incorporate PGx. Further research is needed
to demonstrate the clinical utility and cost-effectiveness of PGx
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on a larger scale, and to develop an evidence base for broader
range of drug classes. Research in the United Kingdom about
patient and HCP perspectives on PGx in psychiatry should seek
to validate the data from studies conducted in other countries.
Implementation science has a role to play in the integration of
PGx into routine mental health clinical practice.
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